• Novartis (NOVN) reaffirmed 2026 guidance: low single-digit sales growth and a low single-digit decline in core operating profit; cites cost controls, acquisitions, and focus on oncology/immunology.
  • Novartis (NOVN) Q2 core EPS $2.41, 12% above estimates. Firm kept guidance and forecasts 2026 core EPS $8.89, assuming buybacks offset higher financing costs. Stock up ~2.1%.
  • Novartis (NOVN) Q2 sales and core earnings beat due to timing: established brands' sales phasing and one‑time Avidity expense timing. Beat may reverse in Q3; guidance unchanged; stock +1.6%.
  • Novartis (NOVN) saw sales lift from Kisqali, Scemblix and Cosentyx; traders watch upcoming late-stage readouts for pelacarsen, remibrutinib and del‑desiran as key catalysts.
  • Novartis CEO Vas Narasimhan will stay on after Q2 profit beat. Management cites H2 trial readouts, product launches next year and ongoing AI transformation—key catalysts for traders to watch.
  • Novartis (NOVN) spent over $15B acquiring Avidity, Tourmaline, Synnovation and Myricx to expand its pipeline and build next‑gen growth medicines — key M&A activity for traders.